Table 1. Kinase activity of TRK inhibitors in clinical use and under development.

Kinase inhibitor: kinase	Larotrectinib	Entrectinib	Selitrectinib	Repotrectinib
TRKA/B/C	+	+	+	+
ROS1		+		+
ALK		+		+
TRKA/B/C on-target mutations			+	+

TRK, tropomyosin receptor kinase.